Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
NCT01495663
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
I-131-CLR1404
Sponsor
Cellectar Biosciences, Inc.